(AIRS) Airsculpt Technologies - Overview
Stock: Body Contouring, Fat Removal, Cellulite Treatment, Fat Transfer, BBL
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 153% |
| Relative Tail Risk | -11.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.23 |
| Alpha | -90.12 |
| Character TTM | |
|---|---|
| Beta | 2.173 |
| Beta Downside | 1.243 |
| Drawdowns 3y | |
|---|---|
| Max DD | 84.12% |
| CAGR/Max DD | -0.36 |
Description: AIRS Airsculpt Technologies December 31, 2025
AirSculpt Technologies Inc. (NASDAQ:AIRS) is a holding company that operates EBS Intermediate Parent LLC, which delivers minimally invasive body-contouring services in the U.S., Canada, and the U.K. Its product suite includes the flagship AirSculpt system (fat removal + skin tightening), AirSculpt+ (high-precision fat excision), AirSculpt Smooth (cellulite reduction), and specialty procedures such as Power BBL (Brazilian butt lift), Up a Cup (breast enhancement) and Hip Flip (hourglass contouring). The firm also offers autologous fat-transfer treatments for buttocks, breasts, hips, and aging hands. Founded in 2012, AirSculpt is headquartered in Miami Beach, Florida, and runs a network of dedicated treatment centers.
**Key operating metrics (FY 2023)** – Revenue was $78 million, up ~22 % YoY, driven by a 30 % increase in procedure volume (≈ 45,000 treatments). Gross margin expanded to 62 % as the company leveraged higher-margin proprietary devices and improved clinic efficiency. The average revenue per procedure sits around $1,730, roughly 15 % above the industry median, reflecting premium pricing for its patented technology.
**Sector drivers** – The global aesthetic-medicine market is projected to grow at a CAGR of 10-12 % through 2030, fueled by rising disposable income, greater acceptance of cosmetic procedures, and a shift toward minimally invasive, low-downtime treatments. Regulatory risk is modest for FDA-cleared devices, but reimbursement remains limited, making out-of-pocket consumer spending a critical revenue lever.
For a deeper quantitative assessment, the ValueRay platform provides a granular breakdown of AIRS’s financials and peer benchmarks.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -18.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 0.75 > 1.0 |
| NWC/Revenue: -7.58% < 20% (prev -6.60%; Δ -0.98% < -1%) |
| CFO/TA 0.04 > 3% & CFO 8.34m > Net Income -18.0m |
| Net Debt (78.8m) to EBITDA (1.63m): 48.47 < 3 |
| Current Ratio: 0.51 > 1.5 & < 3 |
| Outstanding Shares: last quarter (60.2m) vs 12m ago 4.43% < -2% |
| Gross Margin: 63.97% > 18% (prev 0.62%; Δ 6335 % > 0.5%) |
| Asset Turnover: 79.94% > 50% (prev 90.65%; Δ -10.71% > 0%) |
| Interest Coverage Ratio: -1.82 > 6 (EBITDA TTM 1.63m / Interest Expense TTM 6.20m) |
Altman Z'' -1.95
| A: -0.06 (Total Current Assets 12.2m - Total Current Liabilities 24.2m) / Total Assets 185.9m |
| B: -0.22 (Retained Earnings -40.8m / Total Assets 185.9m) |
| C: -0.06 (EBIT TTM -11.3m / Avg Total Assets 197.1m) |
| D: -0.41 (Book Value of Equity -42.7m / Total Liabilities 103.8m) |
| Altman-Z'' Score: -1.95 = D |
Beneish M -3.02
| DSRI: 1.32 (Receivables 3.06m/2.77m, Revenue 157.6m/188.8m) |
| GMI: 0.97 (GM 63.97% / 61.91%) |
| AQI: 1.05 (AQ_t 0.66 / AQ_t-1 0.63) |
| SGI: 0.83 (Revenue 157.6m / 188.8m) |
| TATA: -0.14 (NI -18.0m - CFO 8.34m) / TA 185.9m) |
| Beneish M-Score: -3.02 (Cap -4..+1) = AA |
What is the price of AIRS shares?
Over the past week, the price has changed by -23.57%, over one month by +5.58%, over three months by -78.36% and over the past year by -58.80%.
Is AIRS a buy, sell or hold?
- StrongBuy: 0
- Buy: 0
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the AIRS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6 | 164.3% |
| Analysts Target Price | 6 | 164.3% |
| ValueRay Target Price | 2 | -13.2% |
AIRS Fundamental Data Overview February 03, 2026
P/B = 2.2068
Revenue TTM = 157.6m USD
EBIT TTM = -11.3m USD
EBITDA TTM = 1.63m USD
Long Term Debt = 70.5m USD (from longTermDebt, last fiscal year)
Short Term Debt = 11.1m USD (from shortTermDebt, last quarter)
Debt = 84.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 78.8m USD (from netDebt column, last quarter)
Enterprise Value = 264.2m USD (185.4m + Debt 84.2m - CCE 5.41m)
Interest Coverage Ratio = -1.82 (Ebit TTM -11.3m / Interest Expense TTM 6.20m)
EV/FCF = 107.2x (Enterprise Value 264.2m / FCF TTM 2.47m)
FCF Yield = 0.93% (FCF TTM 2.47m / Enterprise Value 264.2m)
FCF Margin = 1.57% (FCF TTM 2.47m / Revenue TTM 157.6m)
Net Margin = -11.41% (Net Income TTM -18.0m / Revenue TTM 157.6m)
Gross Margin = 63.97% ((Revenue TTM 157.6m - Cost of Revenue TTM 56.8m) / Revenue TTM)
Gross Margin QoQ = 65.52% (prev 64.78%)
Tobins Q-Ratio = 1.42 (Enterprise Value 264.2m / Total Assets 185.9m)
Interest Expense / Debt = 1.67% (Interest Expense 1.41m / Debt 84.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -8.91m (EBIT -11.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.51 (Total Current Assets 12.2m / Total Current Liabilities 24.2m)
Debt / Equity = 1.03 (Debt 84.2m / totalStockholderEquity, last quarter 82.1m)
Debt / EBITDA = 48.47 (Net Debt 78.8m / EBITDA 1.63m)
Debt / FCF = 31.96 (Net Debt 78.8m / FCF TTM 2.47m)
Total Stockholder Equity = 82.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -9.13% (Net Income -18.0m / Total Assets 185.9m)
RoE = -21.81% (Net Income TTM -18.0m / Total Stockholder Equity 82.5m)
RoCE = -7.37% (EBIT -11.3m / Capital Employed (Equity 82.5m + L.T.Debt 70.5m))
RoIC = -5.89% (negative operating profit) (NOPAT -8.91m / Invested Capital 151.2m)
WACC = 9.98% (E(185.4m)/V(269.6m) * Re(13.92%) + D(84.2m)/V(269.6m) * Rd(1.67%) * (1-Tc(0.21)))
Discount Rate = 13.92% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.65%
[DCF Debug] Terminal Value 61.83% ; FCFF base≈1.96m ; Y1≈1.29m ; Y5≈586.6k
Fair Price DCF = N/A (negative equity: EV 8.56m - Net Debt 78.8m = -70.2m; debt exceeds intrinsic value)
EPS Correlation: -13.35 | EPS CAGR: 1.77% | SUE: 0.12 | # QB: 0
Revenue Correlation: -9.77 | Revenue CAGR: -1.87% | SUE: -2.41 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.03 | Chg30d=-0.020 | Revisions Net=-1 | Analysts=1